Evaluation of serum and urine 1,5-anhydro-D-glucitol and myo-inositol concentrations in healthy dogs.
暂无分享,去创建一个
T. Arai | T. Sako | K. Saeki | H. Tazaki | K. Ishioka | H. Oda | A. Mori | Y. Miki | Toko Sato | Noriyuki Hayakawa | Tomoe Niki
[1] Sun Woo Kim,et al. 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. , 2009, Diabetes research and clinical practice.
[2] Shukun Yu. The anhydrofructose pathway of glycogen catabolism , 2008, IUBMB life.
[3] S. Kawazu,et al. [Detection of glucose intolerance by urinary myo-inositol]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[4] S. Kawazu,et al. A study of urinary myo-inositol as a sensitive marker of glucose intolerance. , 2004, Clinica chimica acta; international journal of clinical chemistry.
[5] Y. Akanuma,et al. Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients , 1988, Diabetologia.
[6] Y. Akanuma,et al. Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients , 1988, Diabetologia.
[7] D. Loo,et al. Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus Oocytes , 2004, The Journal of Membrane Biology.
[8] R. Przybylski,et al. Urinary chiro-Inositol and myo-inositol Excretion is Elevated in the Diabetic db/db Mouse and Streptozotocin Diabetic Rat , 2003, Experimental biology and medicine.
[9] D. Gagnon,et al. Identification of a Novel Na+/myo-Inositol Cotransporter* , 2002, The Journal of Biological Chemistry.
[10] B. Keevil,et al. Plasma 1,5‐anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[11] M. Pedersen,et al. Analysis of 1,5-anhydro-D-fructose, microthecin, and 4-deoxy-glycero-hexo-2,3-diulose in algae using gas chromatography-mass spectrometry in selected ion monitoring mode. , 1999, Analytical biochemistry.
[12] R. Farese,et al. In vivo chiro-inositol metabolism in the rat: a defect in chiro-inositol synthesis from myo-inositol and an increased incorporation of chiro-[3H]inositol into phospholipid in the Goto-Kakizaki (G.K) rat. , 1998, Molecules and cells.
[13] E. Reece,et al. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. , 1998, Teratology.
[14] H. Akanuma,et al. Purification and some properties of a hepatic NADPH-dependent reductase that specifically acts on 1,5-anhydro-D-fructose. , 1998, Journal of biochemistry.
[15] J. Nakamura,et al. [Myo-inositol]. , 1998, Nihon rinsho. Japanese journal of clinical medicine.
[16] H. Akanuma,et al. Hepatic production of 1,5-anhydrofructose and 1,5-anhydroglucitol in rat by the third glycogenolytic pathway. , 1996, European journal of biochemistry.
[17] Y. Akanuma,et al. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. , 1994, Diabetes research and clinical practice.
[18] M. Haruna,et al. Effects of 1,5‐anhydro‐D‐fructose on selected glucose‐metabolizing enzymes , 1993, Biotechnology and applied biochemistry.
[19] H. Akanuma,et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. , 1992, The American journal of physiology.
[20] H. Akanuma,et al. High performance liquid chromatographic determination of 1,5-anhydroglucitol in human plasma for diagnosis of diabetes mellitus. , 1992, Biomedical chromatography : BMC.
[21] J. Eichberg,et al. A myo-inositol pool utilized for phosphatidylinositol synthesis is depleted in sciatic nerve from rats with streptozotocin-induced diabetes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[22] Y. Akanuma,et al. Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. , 1990, The American journal of physiology.
[23] Y. Akanuma,et al. Plasma 1,5-Anhydro-D-Glucitol as New Clinical Marker of Glycemic Control in NIDDM Patients , 1989, Diabetes.
[24] Y. Akanuma,et al. Reduced renal reabsorption of 1,5-anhydro-D-glucitol in diabetic rats and mice. , 1987, Journal of biochemistry.
[25] Y. Akanuma,et al. Reduction and Recovery of Plasma 1,5-Anhydro-D-Glucitol Level in Diabetes Mellitus , 1987, Diabetes.
[26] D. Greene,et al. Altered Sorbitol and myo‐Inositol Metabolism as the Basis for Defective Protein Kinase C and (Na,K)‐ATPase Regulation in Diabetic Neuropathy a , 1986, Annals of the New York Academy of Sciences.
[27] O. Takatani,et al. Variations of 1-deoxyglucose(1,5-anhydroglucitol) content in plasma from patients with insulin-dependent diabetes mellitus. , 1983, Clinical chemistry.
[28] O. Takatani,et al. Identification and metabolic implication of 1-deoxyglucose (1,5-anhydroglucitol) in human plasma. , 1982, Clinical chemistry.
[29] E. Pitkänen. Serum 1,5-anhydroglucitol in normal subjects and in patients with insulin-dependent diabetes mellitus. , 1982, Scandinavian journal of clinical and laboratory investigation.
[30] Diethelm Ag,et al. The metabolism of myo-inositol by the human kidney. , 1979 .
[31] R. Clements,et al. The metabolism of myo-inositol by the human kidney. , 1979, The Journal of laboratory and clinical medicine.
[32] P. Thomas,et al. Influence of dietary myoinositol on nerve conduction and inositol phospholipids in normal and diabetic rats. , 1978, Journal of neurology, neurosurgery, and psychiatry.
[33] R. Clements,et al. Myoinositol Metabolism in Diabetes Mellitus: Effect of Insulin Treatment , 1977, Diabetes.